Kyverna Therapeutics (KYTX) to Release Quarterly Earnings on Tuesday

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($1.21) per share for the quarter.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.01). On average, analysts expect Kyverna Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Kyverna Therapeutics Stock Performance

Shares of NASDAQ:KYTX traded down $0.02 on Friday, hitting $2.11. The company's stock had a trading volume of 138,630 shares, compared to its average volume of 413,749. The company has a market capitalization of $91.19 million, a price-to-earnings ratio of -0.61 and a beta of 2.17. Kyverna Therapeutics has a 12 month low of $1.78 and a 12 month high of $17.55. The stock's 50-day moving average is $2.18 and its two-hundred day moving average is $3.37.

Analyst Ratings Changes

KYTX has been the topic of a number of recent analyst reports. HC Wainwright dropped their price target on shares of Kyverna Therapeutics from $6.00 to $4.00 and set a "neutral" rating on the stock in a research report on Thursday, April 3rd. Morgan Stanley dropped their target price on Kyverna Therapeutics from $40.00 to $20.00 and set an "overweight" rating on the stock in a report on Tuesday, April 1st. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Kyverna Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $18.33.

Institutional Investors Weigh In On Kyverna Therapeutics

An institutional investor recently raised its position in Kyverna Therapeutics stock. Bank of America Corp DE lifted its stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 41.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 21,788 shares of the company's stock after purchasing an additional 6,400 shares during the quarter. Bank of America Corp DE owned 0.05% of Kyverna Therapeutics worth $81,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 18.08% of the company's stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.